A Phase 2 interventional study of Apixaban and Vitamin K Antagonist (VKA) in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 46 sites in 14 countries. Open to participants aged 28 Days to 17 Years. Per ClinicalTrials.gov, last updated 2022-10-03.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing apixaban in Thrombosis — 5 open to participants now, 5 under way, 2 of them phase 3. apixaban · Thrombosis.
Among the 18 studies testing apixaban in Thrombosis, this one is the 8th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 8th registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →5 of the 18 studies testing apixaban in Thrombosis are open now, in 3 countries. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–80
Kiranya Arnold · Sites in United States
Ages 18–89
Rushad Patell · Sites in United States
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 16+
Clinical Urology and Epidemiology Working Group · Sites in Finland
Ages 18+
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 28 Days to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 3 · Phase 3 4 · Phase 4 6
First in 2009; this study’s year is marked. 2 started in 2017.
This study's enrollment of 192 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 73 across the 18 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
19 studies in Thrombosis by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 3rd largest by enrollment, is one of 4 that started in 2017, is one of 4 in phase 2, and was the 13th registered.
Bristol-Myers Squibb’s Thrombosis studies by the year they started, since 2006.
2 of the studies testing apixaban in Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06886516Rushad PatellApixaban in Thrombocytopenia | 2027-07-01 |
| NCT07189897Kiranya ArnoldApixaban or Enoxaparin After Head and Neck Cancer Surgery | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing apixaban in Thrombosis, from their registry updates:
Among Bristol-Myers Squibb’s 19 in Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Drug: Apixaban
Drug: Vitamin K Antagonist (VKA) · Drug: Low Molecular Weight Heparin (LMWH)
Specified dose on specified days
Also known as: Eliquis
Specified dose on specified days
Also known as: Warfarin
Specified dose on specified days
Also known as: Enoxaparin
Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events
The number of participants with adjudicated major or CRNM bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding satisfies one or more of the following criteria: fatal bleeding, clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS, or bleeding that requires surgical intervention in an operating suite, including interventional radiology. CRNM bleeding satisfies one or both of the following criteria: overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition or bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room.
Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)
The Number of Participants With Thrombotic Events and Thromboembolic Event-Related Death
The number of participants with thromboembolic events (intra-cardiac, shunt, inside Fontan pathway, pulmonary embolism (PE), stroke, other arterial or venous thromboembolic events, etc.) and thromboembolic event-related death detected by imaging or clinical diagnosis. Death and thromboembolic events are adjudicated by a blinded, independent events adjudication committee (EAC)
Time frame: From randomization to 2 days after last dose (Up to approximately 12 months)
The Number of Participants With Adjudicated Major Bleeding
The number of participants with adjudicated major bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding is defined as bleeding that satisfies one or more of the following criteria: * fatal bleeding * clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period * bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS * bleeding that requires surgical intervention in an operating suite, including interventional radiology
Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)
The Number of Participants With Adjudicated CRNM Bleeding
The number of participants with adjudicated clinically relevant non-major (CRNM) bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. CRNM bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). CRNM bleeding is defined as bleeding that satisfies one or both of the following criteria: * overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition * bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room
Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)
The Number of Participants With All Adjudicated Bleeding
The number of participants with all adjudicated bleeding events
Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)
The Number of Participants With Drug Discontinuation Due to Adverse Effects, Intolerability, or Bleeding
The number of participants with drug discontinuation due to adverse effects, intolerability, or bleeding.
Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)
The Number of Participant Deaths in the Study
The number of participant deaths in the study.
Time frame: From first dose to 2 days after last dose (Up to approximately 12 months)
Maximum Observed Concentration (Cmax)
Time frame: From first dose up to 6 months after first dose
Trough Observed Concentration (Cmin)
Time frame: From first dose up to 6 months after first dose
Area Under the Concentration-Time Curve in One Dosing Interval (AUC (TAU))
Time frame: From first dose up to 6 months after first dose
Time of Maximum Observed Concentration (Tmax)
Time frame: From first dose up to 6 months after first dose
Anti-FXa Activity
Anti-FXa Activity was measured to assess participant plasma apixaban levels. 125 participants received at least one dose of apixaban and had anti-FXa samples collected that contributed measurements to at least one of the timepoints below.
Time frame: From first dose up to 6 months after first dose
Chromogenic FX Assay (Apparent FX Level)
Chromogenic FX was measured to assess (apparent) FX levels in participants and inhibition of FXa by apixaban. 125 participants received at least one dose of apixaban and had chromogenic FX assay samples collected that contributed measurements to at least one of the timepoints below.
Time frame: From first dose up to 6 months after first dose
The Child and Parent Reports of Pediatric Quality of Life Inventory (PedsQL)
Subjects' quality of life was measured using the PedsQL instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. PedsQL consists of 23 items scored on a 5-point Likert scale from 0 (never) to 4 (almost always) or for the child report for younger children ages 5-7, a 3-point Likert scale: 0 (Not at all), 2 (Sometimes), and 4 (A lot). Scores are reverse scored and transformed to a 0-100 scale as follows: 0=100, 1=75, 3=25, 4=0. Higher scores indicate a better HRQOL and/or lower problems.
Time frame: from randomization up to 12 months after randomization
Kids Informed Decrease Complications Learning on Thrombosis (KIDCLOT) IMPACT Score
Subjects' quality of life was measured using the KIDCLOT instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. KIDCLOT Parent inventory uses a 5 point Likert scale from 1 (N/A), 2 (Never), 3 (Rarely), 4 ( Now and then), 5 (Often). Child inventory uses a 4 point Likert scale 1 (N/A), 2 (Never), 3 (Now and then), 5 (Always). Values are scores as follows 1=0, 2=1, 3=2, 4=3, 5=4. Score interpretation is 0 to 100 percent IMPACT of anticoagulation on a child's life therefore, higher scores indicates a more negative effect.
Time frame: from randomization up to 12 months after randomization
| Milestone | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| Started | 129 | 63 |
| Completed | 126 | 62 |
| Not completed | 3 | 1 |
| Withdrew: Participant withdrew consent | 2 | 1 |
| Withdrew: Participant no longer meets study criteria | 1 | 0 |
| Milestone | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| Started | 126 | 62 |
| Completed | 119 | 60 |
| Not completed | 7 | 2 |
| Withdrew: Adverse event | 6 | 1 |
| Withdrew: Participant withdrew consent | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
The number of participants with adjudicated major or CRNM bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding satisfies one or more of the following criteria: fatal bleeding, clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS, or bleeding that requires surgical intervention in an operating suite, including interventional radiology. CRNM bleeding satisfies one or both of the following criteria: overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition or bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room.
| Participants | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events | 1 | 3 |
The number of participants with thromboembolic events (intra-cardiac, shunt, inside Fontan pathway, pulmonary embolism (PE), stroke, other arterial or venous thromboembolic events, etc.) and thromboembolic event-related death detected by imaging or clinical diagnosis. Death and thromboembolic events are adjudicated by a blinded, independent events adjudication committee (EAC)
| Participants | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| Thromboembolic event | 0 | 0 |
| Thromboembolic event-related death | 0 | 0 |
The number of participants with adjudicated major bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). Major bleeding is defined as bleeding that satisfies one or more of the following criteria: * fatal bleeding * clinically overt bleeding associated with a decrease in hemoglobin of at least 20 g/L (i.e., 2 g/dL) in a 24-hour period * bleeding that is retroperitoneal, pulmonary, intracranial, or otherwise involves the CNS * bleeding that requires surgical intervention in an operating suite, including interventional radiology
| Participants | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| The Number of Participants With Adjudicated Major Bleeding | 1 | 1 |
The number of participants with adjudicated clinically relevant non-major (CRNM) bleeding events per the Perinatal and Paediatric Haemostasis Subcommittee of International Society on Thrombosis and Haemostasis (ISTH) criteria. CRNM bleeding events are adjudicated by a blinded, independent events adjudication committee (EAC). CRNM bleeding is defined as bleeding that satisfies one or both of the following criteria: * overt bleeding for which blood product is administered and not directly attributable to the subject's underlying medical condition * bleeding that requires medical or surgical intervention to restore hemostasis, other than in an operating room
| Participants | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| The Number of Participants With Adjudicated CRNM Bleeding | 1 | 2 |
The number of participants with all adjudicated bleeding events
| Participants | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| The Number of Participants With All Adjudicated Bleeding | 47 | 23 |
The number of participants with drug discontinuation due to adverse effects, intolerability, or bleeding.
| Participants | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| The Number of Participants With Drug Discontinuation Due to Adverse Effects, Intolerability, or Bleeding | 7 | 1 |
The number of participant deaths in the study.
| Participants | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| The Number of Participant Deaths in the Study | 0 | 0 |
| ng/mL | Participants Weight Range 6 to < 9 kg | Participants Weight Range 9 to < 12 kg | Participants Weight Range 12 to < 18 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range ≥ 35 kg |
|---|---|---|---|---|---|---|
| Maximum Observed Concentration (Cmax) | 185 ± 48.8 | 218 ± 23.4 | 222 ± 39.6 | 244 ± 30.7 | 249 ± 37.7 | 203 ± 35.9 |
| ng/mL | Participants Weight Range 6 to < 9 kg | Participants Weight Range 9 to < 12 kg | Participants Weight Range 12 to < 18 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range ≥ 35 kg |
|---|---|---|---|---|---|---|
| Trough Observed Concentration (Cmin) | 57.9 ± 90.3 | 82.7 ± 21.5 | 64.3 ± 69.5 | 67.4 ± 58.9 | 73.1 ± 64.7 | 72.7 ± 46.8 |
| ng • h/mL | Participants Weight Range 6 to < 9 kg | Participants Weight Range 9 to < 12 kg | Participants Weight Range 12 to < 18 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range ≥ 35 kg |
|---|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve in One Dosing Interval (AUC (TAU)) | 1460 ± 61.2 | 1840 ± 20.7 | 1610 ± 49.6 | 1760 ± 38.3 | 1840 ± 43.3 | 1630 ± 37.3 |
| hours | Participants Weight Range 6 to < 9 kg | Participants Weight Range 9 to < 12 kg | Participants Weight Range 12 to < 18 kg | Participants Weight Range 18 to < 25 kg | Participants Weight Range 25 to < 35 kg | Participants Weight Range ≥ 35 kg |
|---|---|---|---|---|---|---|
| Time of Maximum Observed Concentration (Tmax) | 2.24 (1.41 to 2.83) | 2.47 (2.23 to 2.71) | 1.72 (0.938 to 3.35) | 1.74 (0.775 to 2.18) | 1.65 (1.26 to 2.85) | 1.85 (1.47 to 2.93) |
Anti-FXa Activity was measured to assess participant plasma apixaban levels. 125 participants received at least one dose of apixaban and had anti-FXa samples collected that contributed measurements to at least one of the timepoints below.
| ng/mL | Apixaban |
|---|---|
| Day 1 (4 HRS POSTDOSE) | 147.69 ± 7.243 |
| Week 2 (PREDOSE) | 86.24 ± 7.652 |
| Week 2 (2 HRS POSTDOSE) | 242.34 ± 18.966 |
| Month 3 (2 HRS POSTDOSE) | 228.88 ± 14.263 |
| Month 6 (PREDOSE) | 66.93 ± 6.532 |
Chromogenic FX was measured to assess (apparent) FX levels in participants and inhibition of FXa by apixaban. 125 participants received at least one dose of apixaban and had chromogenic FX assay samples collected that contributed measurements to at least one of the timepoints below.
| Percent | Apixaban |
|---|---|
| Day 1 (PREDOSE) | 58.87 ± 2.368 |
| Day 1 (4 HRS POSTDOSE) | 18.90 ± 1.205 |
| Week 2 (PREDOSE) | 35.88 ± 1.973 |
| Week 2 (2 HRS POSTDOSE) | 21.26 ± 1.680 |
| Month 3 (2 HRS POSTDOSE) | 18.25 ± 0.970 |
| Month 6 (PREDOSE) | 36.57 ± 1.943 |
Subjects' quality of life was measured using the PedsQL instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. PedsQL consists of 23 items scored on a 5-point Likert scale from 0 (never) to 4 (almost always) or for the child report for younger children ages 5-7, a 3-point Likert scale: 0 (Not at all), 2 (Sometimes), and 4 (A lot). Scores are reverse scored and transformed to a 0-100 scale as follows: 0=100, 1=75, 3=25, 4=0. Higher scores indicate a better HRQOL and/or lower problems.
| Score on a scale | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| GENERAL-SPECIFIC MODULE ASSESSED BY CHILD - BASELINE | 69.64 ± 15.512 | 60.71 ± 17.374 |
| GENERAL-SPECIFIC MODULE ASSESSED BY CHILD - MONTH 12 | 73.37 ± 19.998 | 64.81 ± 22.327 |
| GENERAL-SPECIFIC MODULE ASSESSED BY PARENT - BASELINE | 65.61 ± 16.625 | 65.42 ± 18.000 |
| GENERAL-SPECIFIC MODULE ASSESSED BY PARENT - MONTH 12 | 70.00 ± 19.560 | 70.32 ± 21.949 |
| HEART PROBLEMS AND TREATMENT ASSESSED BY CHILD - BASELINE | 65.34 ± 22.130 | 64.70 ± 18.465 |
| HEART PROBLEMS AND TREATMENT ASSESSED BY CHILD - MONTH 12 | 69.46 ± 21.119 | 63.44 ± 19.836 |
| TREATMENT II ASSESSED BY CHILD - BASELINE | 87.39 ± 22.994 | 85.68 ± 15.857 |
| TREATMENT II ASSESSED BY CHILD - MONTH 12 | 91.77 ± 10.896 | 86.27 ± 16.400 |
| PERCEIVED PHYSICAL APPEARANCE ASSESSED BY CHILD - BASELINE | 75.51 ± 27.477 | 78.44 ± 23.390 |
| PERCEIVED PHYSICAL APPEARANCE ASSESSED BY CHILD - MONTH 12 | 80.56 ± 22.408 | 81.37 ± 30.689 |
| TREATMENT ANXIETY ASSESSED BY CHILD - BASELINE | 80.52 ± 23.420 | 60.31 ± 34.162 |
| TREATMENT ANXIETY ASSESSED BY CHILD - MONTH 12 | 80.71 ± 25.480 | 60.31 ± 38.333 |
| COGNITIVE PROBLEMS ASSESSED BY CHILD - BASELINE | 69.85 ± 20.871 | 53.24 ± 20.382 |
| COGNITIVE PROBLEMS ASSESSED BY CHILD - MONTH 12 | 68.24 ± 24.367 | 53.53 ± 26.796 |
| COMMUNICATION ASSESSED BY CHILD - BASELINE | 66.15 ± 30.000 | 63.55 ± 28.998 |
| COMMUNICATION ASSESSED BY CHILD - MONTH 12 | 70.31 ± 26.681 | 57.28 ± 38.948 |
| HEART PROBLEMS AND TREATMENT ASSESSED BY PARENT - BASELINE | 63.68 ± 20.727 | 67.71 ± 22.668 |
| HEART PROBLEMS AND TREATMENT ASSESSED BY PARENT - MONTH 12 | 66.37 ± 20.811 | 69.00 ± 23.688 |
| TREATMENT II ASSESSED BY PARENT - BASELINE | 91.41 ± 11.557 | 85.27 ± 17.325 |
| TREATMENT II ASSESSED BY PARENT - MONTH 12 | 90.30 ± 12.381 | 83.80 ± 18.915 |
| PERCEIVED PHYSICAL APPEARANCE ASSESSED BY PARENT - BASELINE | 79.16 ± 22.571 | 79.66 ± 22.958 |
| PERCEIVED PHYSICAL APPEARANCE ASSESSED BY PARENT - MONTH 12 | 79.38 ± 21.012 | 74.33 ± 26.998 |
| TREATMENT ANXIETY ASSESSED BY PARENT - BASELINE | 61.44 ± 30.804 | 56.27 ± 33.997 |
| TREATMENT ANXIETY ASSESSED BY PARENT - MONTH 12 | 64.03 ± 29.567 | 57.77 ± 34.199 |
| COGNITIVE PROBLEMS ASSESSED BY PARENT - BASELINE | 60.29 ± 29.558 | 61.60 ± 25.807 |
| COGNITIVE PROBLEMS ASSESSED BY PARENT - MONTH 12 | 58.69 ± 29.560 | 58.53 ± 33.432 |
| COMMUNICATION ASSESSED BY PARENT - BASELINE | 65.57 ± 27.342 | 67.33 ± 28.257 |
| COMMUNICATION ASSESSED BY PARENT - MONTH 12 | 68.20 ± 24.037 | 66.17 ± 28.067 |
Subjects' quality of life was measured using the KIDCLOT instrument administered only to English-speaking children/parents. Only subjects who completed the questionnaires at both baseline and post-baseline visits were included in the analyses. KIDCLOT Parent inventory uses a 5 point Likert scale from 1 (N/A), 2 (Never), 3 (Rarely), 4 ( Now and then), 5 (Often). Child inventory uses a 4 point Likert scale 1 (N/A), 2 (Never), 3 (Now and then), 5 (Always). Values are scores as follows 1=0, 2=1, 3=2, 4=3, 5=4. Score interpretation is 0 to 100 percent IMPACT of anticoagulation on a child's life therefore, higher scores indicates a more negative effect.
| Score on a scale | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| BASELINE CHILD REPORTED - 6 MONTHS | 24.35 ± 12.887 | 26.45 ± 12.114 |
| POST BASELINE CHILD REPORTED - 6 MONTHS | 22.81 ± 13.380 | 22.57 ± 16.049 |
| BASELINE CHILD REPORTED - 12 MONTHS | 22.50 ± 11.787 | 25.32 ± 11.719 |
| POST BASELINE CHILD REPORTED - 12 MONTHS | 21.52 ± 13.251 | 18.01 ± 10.408 |
| BASELINE PARENT REPORTED - 6 MONTHS | 37.97 ± 20.493 | 39.02 ± 17.932 |
| POST BASELINE PARENT REPORTED - 6 MONTHS | 32.32 ± 17.060 | 37.94 ± 20.626 |
| BASELINE PARENT REPORTED - 12 MONTHS | 38.37 ± 18.874 | 39.36 ± 16.057 |
| POST BASELINE PARENT REPORTED - 12 MONTHS | 31.10 ± 16.021 | 33.61 ± 17.943 |
Collected over AEs are collected from the first dose date until the last dose date + 2 days/ SAEs are collected from the first dose date until the last dose date + 30 days (Up to approximately 13 months) Participants were assessed for All Cause Mortality from their first dose until the study was completed (up to approximately 57 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apixaban | 0/126 (0%) | 26/126 (20.6%) | 68/126 (54%) |
| Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) | 0/62 (0%) | 13/62 (21%) | 36/62 (58.1%) |
| Event | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| ArrhythmiaCardiac disorders | 1/126 | 1/62 |
| Atrial septal defect acquiredCardiac disorders | 0/126 | 1/62 |
| Supraventricular tachycardiaCardiac disorders | 0/126 | 1/62 |
| Congenital cystic kidney diseaseCongenital, familial and genetic disorders | 0/126 | 1/62 |
| Hypoplastic left heart syndromeCongenital, familial and genetic disorders | 0/126 | 1/62 |
| Gingival bleedingGastrointestinal disorders | 0/126 | 1/62 |
| HaematocheziaGastrointestinal disorders | 0/126 | 1/62 |
| Protein-losing gastroenteropathyGastrointestinal disorders | 1/126 | 1/62 |
| COVID-19Infections and infestations | 1/126 | 1/62 |
| InfluenzaInfections and infestations | 1/126 | 1/62 |
| Event | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) |
|---|---|---|
| VomitingGastrointestinal disorders | 20/126 | 9/62 |
| PyrexiaGeneral disorders | 20/126 | 8/62 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 20/126 | 6/62 |
| HeadacheNervous system disorders | 19/126 | 3/62 |
| NasopharyngitisInfections and infestations | 13/126 | 8/62 |
| Upper respiratory tract infectionInfections and infestations | 14/126 | 4/62 |
| DiarrhoeaGastrointestinal disorders | 12/126 | 4/62 |
| ContusionInjury, poisoning and procedural complications | 9/126 | 5/62 |
| GastroenteritisInfections and infestations | 7/126 | 4/62 |
| International normalised ratio increasedInvestigations | 0/126 | 4/62 |
| Age, Continuous(Years) | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) | Total |
|---|---|---|---|
| Mean | 7.96 ± 4.553 | 7.56 ± 4.408 | 7.83 ± 4.499 |
| Age, Customized(Participants) | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) | Total |
|---|---|---|---|
| 28 DAYS - < 2 YEARS | 8 | 3 | 11 |
| 2 YEARS - < 6 YEARS | 40 | 22 | 62 |
| 6 YEARS - < 12 YEARS | 49 | 23 | 72 |
| 12 YEARS - < 18 YEARS | 32 | 15 | 47 |
| Sex: Female, Male(Participants) | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) | Total |
|---|---|---|---|
| Female | 67 | 23 | 90 |
| Male | 62 | 40 | 102 |
| Ethnicity (NIH/OMB)(Participants) | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) | Total |
|---|---|---|---|
| Hispanic or Latino | 20 | 14 | 34 |
| Not Hispanic or Latino | 105 | 47 | 152 |
| Unknown or Not Reported | 4 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Apixaban | Low Molecular Weight Heparin (LMWH)/Vitamin K Antagonists (VKA) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 6 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 2 | 9 |
| White | 109 | 51 | 160 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Oct 2021, 56 months.
Results were first posted in May 2022, 7 months after primary completion.
Of 22 phase 2 interventional studies under Thrombosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's 56 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban